Boston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025.
Boston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio
